ATE540694T1 - Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig - Google Patents

Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig

Info

Publication number
ATE540694T1
ATE540694T1 AT01996390T AT01996390T ATE540694T1 AT E540694 T1 ATE540694 T1 AT E540694T1 AT 01996390 T AT01996390 T AT 01996390T AT 01996390 T AT01996390 T AT 01996390T AT E540694 T1 ATE540694 T1 AT E540694T1
Authority
AT
Austria
Prior art keywords
ivig
monoclonal
treating thrombocytopenia
thrombocytopenia
composition
Prior art date
Application number
AT01996390T
Other languages
English (en)
Inventor
Alan Lazarus
John Freedman
Seng Song
Andrew Crow
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of ATE540694T1 publication Critical patent/ATE540694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01996390T 2000-11-20 2001-11-20 Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig ATE540694T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
PCT/CA2001/001648 WO2002040047A2 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
ATE540694T1 true ATE540694T1 (de) 2012-01-15

Family

ID=22943488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996390T ATE540694T1 (de) 2000-11-20 2001-11-20 Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig

Country Status (7)

Country Link
US (1) US20040047862A1 (de)
EP (2) EP1370288B1 (de)
AT (1) ATE540694T1 (de)
AU (1) AU2002220404A1 (de)
CA (2) CA2856033C (de)
DK (2) DK1370288T3 (de)
WO (1) WO2002040047A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1737487B1 (de) * 2004-03-30 2016-05-25 Canadian Blood Services Verfahren zur behandlung von autoimmunkrankheiten mit antikörpern
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2011517960A (ja) 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
WO2014093417A1 (en) * 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
MX386491B (es) 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
BR112021024632A2 (pt) 2019-06-07 2022-01-18 Argenx Bvba Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025229206A1 (en) 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (ja) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd 血液凝固異常治療剤
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
IL146005A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
CA2467781C (en) 2014-09-23
CA2856033A1 (en) 2002-05-23
EP2283861B1 (de) 2016-01-27
CA2467781A1 (en) 2002-05-23
DK2283861T3 (en) 2016-02-15
EP1370288B1 (de) 2012-01-11
WO2002040047A3 (en) 2003-10-02
AU2002220404A1 (en) 2002-05-27
EP2283861A3 (de) 2013-05-29
EP2283861A2 (de) 2011-02-16
DK1370288T3 (da) 2012-03-05
US20040047862A1 (en) 2004-03-11
WO2002040047A2 (en) 2002-05-23
CA2856033C (en) 2015-11-03
EP1370288A2 (de) 2003-12-17

Similar Documents

Publication Publication Date Title
DK1370288T3 (da) Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG
DE602004030535D1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
ATE458491T1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
ATE447587T1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
HRP20110758T1 (en) Il-17 antagonistic antibodies
RS20060171A (en) Antibodies to m-csf
PL370514A1 (en) Antibodies to cd40
SG142330A1 (en) Anti-cd38 human antibodies and uses therefor
EA200702327A1 (ru) Антитела к миостатину
DK3284753T3 (da) Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
CY1109423T1 (el) Ανθρωπινα μονοκλωνα αντισωματα αντι-ιντελευκινης-5 και μεθοδοι και συνθεσεις που τα περιεχουν
DE602005020743D1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
JP2003534781A5 (de)
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
RU2011104709A (ru) Фармацевтическая композиция для лечения и предупреждения рака
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
RU2019103991A (ru) Анти-il-22r-антитела
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60217912D1 (de) Verfahren zur behandlung eines gasgemisches durch adsorption